[Value of a model based on PIRO conception in predicting the prognosis in critical patients]

Tao Wang1, Yun-liang Cui, Zhi-xiang Chu

  • 1Department of Emergency, Hainan Branch of PLA General Hospital, Sanya 572000, Hainan, China. Corresponding author: Ban Yu,

Insights

The PIRO system, incorporating predisposition, injury, response, and organ dysfunction, effectively predicts 28-day mortality in critical patients. Key factors include underlying disease scores, severe sepsis/septic shock, and Sequential Organ Failure Assessment (SOFA) scores.

Area of Science:

  • Critical care medicine
  • Prognostic modeling
  • Clinical epidemiology

Context:

  • Critical illness presents a significant challenge in predicting patient outcomes.
  • Existing prognostic models may not fully capture the complexity of critical patient trajectories.
  • The PIRO (Predisposition, Injury, Response, Organ dysfunction) concept offers a framework for assessing critical illness severity.

Purpose:

  • To evaluate the predictive value of factors derived from the PIRO concept for 28-day mortality in critically ill patients.
  • To identify independent predictors of mortality within the PIRO framework using multivariate logistic regression.
  • To assess the performance of a PIRO-based prognostic model compared to individual clinical variables.

Summary:

  • A retrospective analysis of 187 critical patients identified underlying disease scores, severe sepsis/septic shock, and Sequential Organ Failure Assessment (SOFA) scores as independent predictors of 28-day mortality.
  • The PIRO model, utilizing these factors, demonstrated a high area under the receiver operating characteristic curve (AUC) of 0.871, indicating strong prognostic value.
  • The developed PIRO-based model showed superior predictive accuracy for mortality compared to individual components like SOFA, APS, underlying disease scores, PCT, and age.

Impact:

  • The findings suggest that a PIRO-based multivariate regression model can significantly enhance the prediction of 28-day mortality in critical care settings.
  • This prognostic tool can aid clinicians in risk stratification and timely intervention for critically ill patients.
  • The study validates the utility of the PIRO concept in developing robust clinical prediction models for critical illness outcomes.
Abstract

Related Concept Videos

Sensitivity, Specificity, and Predicted Value01:13

Sensitivity, Specificity, and Predicted Value

In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
1.9K
Decision Making: P-value Method01:09

Decision Making: P-value Method

The process of hypothesis testing based on the P-value method includes calculating the P- value using the sample data and interpreting it.
First, a specific claim about the population parameter is proposed. The claim is based on the research question and is stated in a simple form. Further, an opposing statement to the claim  is also stated. These statements can act as null and alternative hypotheses:  a null hypothesis would be a neutral statement while the alternative hypothesis can...
5.8K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97